Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

On June 23, Eli Lilly and Company (NYSE:LLY) declared a quarterly dividend of $1.50 per share, which was in line with its ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Eli Lilly's (LLY) Potential New Products Key to Growth August 15, 2022 — 10:15 am EDT Written by Zacks Equity Research for Zacks -> ...

Eli Lilly Just Added Another Potential Billion ... Billionaire Stanley Druckenmiller Has Unloaded Shares of Last Year's 2 Top Performing AI Stocks and Is Piling Into a Growth Stock That Has ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

There's so much growth on the horizon for Eli Lilly, and with the stock's payout ratio still at a fairly modest 54% of earnings, there is more room for the business to continue making generous ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a ...

Eli Lilly didn't generate much growth last year, but its future looks promising. Mounjaro has the potential to be a game-changing product for the business. It could significantly propel the ...

Eli Lilly Earnings: Solid Results and Strong Mounjaro Data Set Up Robust Long-Term Growth Potential Despite potential for Lilly’s growth, we remain concerned about the stock’s valuation.